Pineno Levin & Ford Asset Management Inc. Has $5.35 Million Position in Pfizer Inc. (PFE)

Pineno Levin & Ford Asset Management Inc. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 149,922 shares of the biopharmaceutical company’s stock after selling 4,349 shares during the period. Pfizer comprises 2.5% of Pineno Levin & Ford Asset Management Inc.’s holdings, making the stock its 11th largest position. Pineno Levin & Ford Asset Management Inc.’s holdings in Pfizer were worth $5,352,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Shine Investment Advisory Services Inc. purchased a new position in Pfizer during the second quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer during the second quarter worth approximately $103,000. D. Scott Neal Inc. boosted its position in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares in the last quarter. Herndon Capital Management LLC purchased a new position in Pfizer during the second quarter worth approximately $120,000. Finally, Private Vista LLC boosted its position in Pfizer by 2,277.3% during the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares in the last quarter. 69.75% of the stock is currently owned by hedge funds and other institutional investors.

In related news, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the transaction, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,800 shares of company stock worth $1,327,248. Company insiders own 0.06% of the company’s stock.

A number of equities analysts have issued reports on the company. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Friday, December 15th. Jefferies Group set a $38.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, October 31st. Finally, Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $38.77.

Pfizer Inc. (PFE) opened at $36.14 on Tuesday. The firm has a market capitalization of $215,419.95, a P/E ratio of 22.31, a PEG ratio of 2.55 and a beta of 1.01. Pfizer Inc. has a 1 year low of $30.90 and a 1 year high of $37.35. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the business posted $0.61 earnings per share. sell-side analysts expect that Pfizer Inc. will post 2.59 EPS for the current year.

Pfizer declared that its Board of Directors has approved a share buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its stock is undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.76%. The ex-dividend date of this dividend is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is 79.01%.

TRADEMARK VIOLATION NOTICE: “Pineno Levin & Ford Asset Management Inc. Has $5.35 Million Position in Pfizer Inc. (PFE)” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/26/pineno-levin-ford-asset-management-inc-has-5-35-million-position-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit